Jenny Niederjohn
About Jenny Niederjohn
Jenny Niederjohn is a Process Engineer III at Bristol Myers Squibb in Bothell, Washington, with over two decades of experience in the biotechnology and pharmaceutical industries.
Current Role at Bristol Myers Squibb
Jenny Niederjohn is currently employed as a Process Engineer III at Bristol Myers Squibb in Bothell, Washington, United States. In this position, she focuses on the development and optimization of manufacturing processes within the pharmaceutical industry. Her role involves designing, implementing, and managing engineering projects that align with the company's production goals.
Previous Position at Dendreon
From 2017 to 2021, Jenny Niederjohn served as a Process Scientist at Dendreon. During her four-year tenure, she focused on the development and enhancement of cellular therapies. Her responsibilities included overseeing laboratory activities, ensuring compliance with regulatory standards, and improving process efficiencies.
Early Career Experience
Jenny Niederjohn's extensive career in biotechnology and pharmaceuticals began at Cadus Pharmaceuticals, where she worked as an Associate Research Scientist from 1996 to 1999. This was followed by a role as a Senior Associate Scientist at Bayer Pharmaceuticals from 1999 to 2004. During these years, she contributed to significant scientific projects and drug discovery efforts.
Academic Background
Jenny Niederjohn holds a Master of Science (MS) degree in Cell and Molecular Biology from the University of New Haven, which she earned from 2000 to 2002. Prior to that, she obtained a Bachelor's degree in General Biology from the University of Colorado Denver, studying from 1992 to 1997. Her academic training laid a solid foundation for her career in scientific research.
Contributions to Drug Discovery
In 2015, Jenny Niederjohn worked as a Drug Discovery Scientist at Vanderbilt University for 11 months. In this role, she contributed to the development of new therapeutic compounds. Her efforts in drug discovery played a part in advancing potential new treatments in the pharmaceutical field.